Knoll Capital Management, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Knoll Capital Management, LLC

$148 Million
Q2 2024

A detailed history of Knoll Capital Management, LLC transactions in Biohaven Pharmaceutical Holding CO Ltd. stock. As of the latest transaction made, Knoll Capital Management, LLC holds 710,422 shares of BHVN stock, worth $36.2 Million. This represents 16.66% of its overall portfolio holdings.

Number of Shares

710,422

Previous 490,422 44.86%

Holding current value

$36.2 Million

Previous $26.8 Million 8.06%

% of portfolio

16.66%

Previous 16.74%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$32.77 - $53.49 $7.21 Million - $11.8 Million	220,000 Added 44.86%	710,422 $24.7 Million
Q3 2023 Nov 14, 2023	BUY	$16.93 - $26.41 $677,200 - $1.06 Million	40,000 Added 8.88%	490,422 $12.8 Million
Q4 2022 Feb 14, 2023	SELL	$7.0 - $16.87 $3.15 Million - $7.6 Million	-450,422 Reduced 50.0%	450,422 $6.25 Million
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $440,320 - $571,680	4,000 Added 0.45%	900,844 $107 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $3.99 Million - $5.94 Million	40,000 Added 4.67%	896,844 $124 Million
Q1 2021 Jun 14, 2021	SELL	$64.07 - $91.75 $41,645 - $59,637	-650 Reduced 0.08%	856,844 $58.6 Million
Q3 2019 Nov 14, 2019	BUY	$37.38 - $49.47 $4.03 Million - $5.33 Million	107,679 Added 14.36%	857,494 $35.8 Million
Q1 2018 May 15, 2018	SELL	$22.49 - $34.56 $1.29 Million - $1.98 Million	-57,409 Reduced 7.11%	749,815 $19.3 Million
Q3 2017 Nov 14, 2017	BUY	$23.54 - $38.21 $19 Million - $30.8 Million	807,224	807,224 $30.2 Million

Others Institutions Holding BHVN

# of Institutions

Shares Held

785K

Call Options Held

Put Options Held

View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

More about BHVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Knoll Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Knoll Capital Management, LLC with notifications on news.

Account

Knoll Capital Management, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History